The timing of hormonal treatment for prostate cancer.
This article reviews publications investigating the optimal timing of androgen ablative therapy for prostate cancer. We regard with some concern retrospective series, the use of endpoints other than overall survival, the presentation of actuarial and not actual survival, and the omission of appropriate controls. Treatment of minimal residual disease and other clinical scenarios are explored.